Viemed Healthcare, Inc.
NASDAQ:VMDMedical - Devices
+$0.07 today
- Market cap
- $332.70M
- Beta
- 1.13
- P/E (TTM)
- 27.4
- EPS (TTM)
- $0.39
Volume 0.26M
Average 0.26M
VMD Depreciation & Amortization
Non-cash expense that spreads the cost of physical and intangible assets over their useful lives.
Viemed Healthcare, Inc.NASDAQ: VMD
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization grows in line with its trailing trend
Q1 FY2026 depreciation & amortization of $7.62M rose 15.2% year over year, in line with the +15.3% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 0.7% from the prior quarter. Over 3 fiscal years it compounded at +22.3% a year.
Context
- Depreciation & amortization amounted to 10.6% of revenue in FY2025, down 0.7 pp from a year earlier.
- Depreciation & amortization increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +15.2% toward the trailing-twelve-month pace of +15.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the income statement
- Latest · FY2025
- 28.61M USD
- Year-over-year change
- +12.8%
- 4-year CAGR
- +26.1%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 28.61M | +12.8% |
| FY2024 | 2024-12-31 | 25.37M | +16.0% |
| FY2023 | 2023-12-31 | 21.86M | +39.9% |
| FY2022 | 2022-12-31 | 15.63M | +38.2% |
| FY2021 | 2021-12-31 | 11.31M | — |
Depreciation & Amortization vs competitors
How VMD compares with its peers on the latest reported figures
- VMD's LTM Mar 2026 depreciation & amortization of $29.62M is the highest of the 11 companies compared; the peer median is $2.21M.
- Its year-over-year change of +15.3% is the 5th highest of 11, against a peer median of -0.7%.
- Depreciation & amortization amounts to 10.3% of revenue for VMD, versus a peer median of 3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $29.62M | +15.3% | +22.3% | 10.3% | |
| LTM Mar 2026 | $21.08M | +133.7% | +51.8% | 14.5% | |
| LTM Mar 2026 | $20.37M | -2.6% | -4.2% | 5.8% | |
| LTM Dec 2025 | $11.7M | -0.3% | +0.5% | 89.8% | |
| LTM Mar 2026 | $4.32M | -7.0% | +40.4% | 7.5% | |
| LTM Mar 2026 | $2.74M | -56.6% | -11.6% | 2.3% | |
| LTM Mar 2026 | $1.67M | -1.0% | +15.4% | 4.1% | |
| LTM Mar 2026 | $1.59M | +32.3% | +10.5% | 3.6% | |
| LTM Mar 2026 | $1.2M | +21.9% | +23.1% | 1.7% | |
| LTM Mar 2026 | $777K | +15.6% | +22.4% | 1.3% | |
| LTM Mar 2026 | $441K | -24.4% | -27.0% | 0.6% | |
| Peer median (excluding VMD) | $2.21M | -0.7% | +12.9% | 3.8% | |
Competitors are the stored peer set for VMD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 117.06M | 138.83M | 183.01M | 224.26M | 270.28M |
| Cost of Revenue | 43.65M | 54.15M | 70.23M | 91.05M | 114.82M |
| Gross Profit | 73.41M | 84.68M | 112.78M | 133.2M | 155.46M |
| Gross Margin | 62.7% | 61.0% | 61.6% | 59.4% | 57.5% |
| Research & Development | 2.11M | 2.7M | 2.78M | 3.07M | 3.02M |
| Selling, General & Admin | 60.04M | 73.36M | 93.73M | 112.48M | 130.5M |
| Operating Expenses | 61.83M | 76.43M | 98.45M | 115.3M | 134.75M |
| Depreciation & Amortization | 11.31M | 15.63M | 21.86M | 25.37M | 28.61M |
| EBITDA | 24.13M | 24.82M | 36.68M | 42.31M | 51.56M |
| EBITDA Margin | 20.6% | 17.9% | 20.0% | 18.9% | 19.1% |
| Operating Income | 11.58M | 8.25M | 14.33M | 17.9M | 20.71M |
| Operating Margin | 9.9% | 5.9% | 7.8% | 8.0% | 7.7% |
| Interest Income | 0 | 0 | 0 | 0 | 0 |
| Interest Expense | 318K | 197K | 424K | 776K | 1.18M |
| Other Income / Expenses | 923K | 738K | 61K | (1.73M) | 1.06M |
| Income Before Tax | 12.5M | 8.99M | 14.39M | 16.17M | 21.77M |
| Pre-Tax Margin | 10.7% | 6.5% | 7.9% | 7.2% | 8.1% |
| Income Tax Expense | 3.38M | 2.77M | 4.15M | 4.76M | 6.39M |
| Net Income | 9.13M | 6.22M | 10.24M | 11.27M | 14.93M |
| Net Margin | 7.8% | 4.5% | 5.6% | 5.0% | 5.5% |
| EPS (Basic) | 0.23 | 0.15 | 0.27 | 0.29 | 0.38 |
| EPS (Diluted) | 0.22 | 0.15 | 0.25 | 0.28 | 0.37 |
| Weighted Avg Shares | 39.49M | 38.66M | 38.35M | 38.76M | 38.9M |
| Weighted Avg Shares (Diluted) | 40.68M | 39.81M | 40.38M | 40.81M | 40.82M |
Viemed Healthcare, Inc.
NASDAQ:VMD
Intrinsic Alpha fair value
Locked
Current Price
$8.78
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.